Innovation Center for Advanced Therapies (ICAT)

What Innovation Center for Advanced Therapies (ICAT) does

The Innovation Center for Advanced Therapies (ICAT) is a Dutch non-profit innovation center headquartered at Utrecht Science Park Zeist (Utrechtseweg 48, 3704 HE) and operationally embedded within UMC Utrecht. Established in 2021 with €12.7 million from the Dutch National Growth Fund as part of the broader €56 million RegMed XB Pilot Factory initiative, ICAT's stated mission is to accelerate the translation of advanced cell, gene, and tissue therapies (ATMPs) from research into clinical practice. The center operates three integrated facilities: a Shared Innovation Lab for proof-of-concept and early-stage development, a GMP Simulation Facility for process development, optimization, and validation, and a GMP Production Facility (planned at six cleanrooms) operating under a GMP manufacturer license with QP batch release handled by UMC Utrecht Pharmacy.

The platform supports therapeutic areas across Cells (autologous/allogeneic cell processing, JACIE-certified stem cell processing, ex vivo non-viral gene editing), Genes (in-house lentiviral, AAV, and adenoviral vector production plus non-viral delivery including lipid nanoparticles and electroporation), and Tissues (3D bioprinting, bio-ink development, organ-on-chip systems). Supporting services include ATMP-specific CMC consulting, Quality by Design and regulatory affairs with EMA and CBG connections, a two-year life-sciences startup incubation program run jointly with UtrechtInc, and education offerings such as the Organ-on-chip MasterClass (priced at €1,395–€2,400 per participant) and the RegMed XB Annual Conference (€299–€399). Revenue is generated through a mix of recurring lab memberships and equipment rentals, project-based CMC and GMP manufacturing services, training fees, and ongoing public funding from the National Growth Fund and Province of Utrecht. The customer base is segmented into academic institutions and researchers, life-sciences startups and scale-ups, and commercial organizations of varying sizes, with clinicians as a secondary persona.

ICAT is part of the RegMed XB consortium spanning four Dutch regenerative-medicine clusters (Leiden, Utrecht, Eindhoven, Maastricht) plus Leuven, and collaborates with partners including NXTGEN Hightech, Biotech Booster, Oncode Accelerator, the Hubrecht Institute, Utrecht University, and Prinses Máxima Center for Pediatric Oncology. As of 2026, ICAT is moving into the Plus Ultra Utrecht facility at Utrecht Science Park, where it will operate the Shared Open Innovation Lab within a 23,000 m² Kadans-managed building.

Name

Innovation Center for Advanced Therapies (ICAT)

Legal name

Innovation Center for Advanced Therapies (ICAT)

Website

https://icat-utrecht.nl

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

The Innovation Center for Advanced Therapies (ICAT) is a Utrecht-based, non-profit innovation center founded in 2021 that operates three integrated facilities — Shared Innovation Lab, GMP Simulation Facility, and GMP Production Facility — to translate advanced cell, gene, and tissue therapies from research into clinical use for academic institutions, life-sciences startups, and commercial organizations.

Ownership category

akta.pro rank

Headquarters

HQ city

Zeist

HQ country

Netherlands

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Lab Memberships and Hourly Equipment Rentals: Shared Innovation Lab offers lab memberships and hourly rentals of specialized equipment for cell processing, 3D bioprinting, and analytical equipment
2. CMC Services: Chemistry, Manufacturing & Controls services specific to ATMPs including process development, analytical development, feasibility studies, and comparability studies
3. GMP Manufacturing Services: GMP production and certification services for ATMPs with QP batch release through UMC Utrecht Pharmacy
4. Training and Education: Seminars, trainings, workshops in ATMPs, and the annual Organ-on-chip MasterClass
5. National Growth Fund: Government funding of €12.7 million awarded to establish ICAT as part of RegMed XB Pilot Factory infrastructure

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

ICAT is a non-profit innovation center that provides integrated infrastructure and services for the development of advanced cell, gene, and tissue therapies (ATMPs). It operates three co-located facilities — a Shared Innovation Lab for early-stage proof of concept, a GMP Simulation Facility for process development and validation, and a GMP Production Facility for clinical-grade ATMP manufacturing — and offers specialized services in cell therapy, gene therapy, biofabrication, CMC consulting, and startup incubation.

Product overview

ICAT is an innovation center that provides an integrated platform for developing advanced cell, gene, and tissue therapies. The organization operates three interconnected facilities: the Shared Innovation Lab for early-stage proof of concept, the GMP Simulation Facility for process development and validation, and the GMP Production Facility for clinical-grade ATMP manufacturing. These core facilities are supported by specialized services including CMC (Chemistry, Manufacturing & Controls), strategic development/Quality by Design consulting, a two-year start-up incubation program, and education/networking events. The platform focuses on therapeutic areas of Cells (cell therapy services), Genes (gene therapy services), and Tissues (biofabrication services), enabling a complete roadmap from early-stage development through GMP production for clinical application.

Differentiator

Problem solved

Functional benefit

Products and services

• Shared Innovation Lab Open innovation lab environment for proof of concept and early-stage development of advanced therapies, offering lab memberships and hourly rentals of specialized equipment including cell processing platforms, analytical equipment, and 3D bioprinting technologies.
• GMP Simulation Facility Facility focused on translating new innovations towards GMP production for clinical application, providing process development, optimization, validation, and GMP-compliant documentation services to bridge research and production.
• GMP Production Facility State-of-the-art cleanroom facility with GMP manufacturer license for production of Advanced Therapy Medicinal Products (ATMPs), providing batch release certification through UMC Utrecht Pharmacy and storage of final products.
• CMC Services (Chemistry, Manufacturing & Controls) Comprehensive CMC services specific to ATMPs including process development, scale-up, analytical development, feasibility studies, comparability studies, gap analysis, risk assessment, and stability studies.
• Cell Therapy Services Comprehensive cell therapy services including autologous and allogeneic cell processing, GMP-compliant cell expansion, cell sorting/transduction/electroporation, ex vivo gene editing, JACIE-certified stem cell processing, quality control, and cryopreservation.
• Gene Therapy Services Gene therapy services including in-house viral vector production platform, GMP upstream/downstream processing, gene editing and CRISPR applications, viral vector characterization, and regulatory compliance for gene therapies.
• Biofabrication Services Biofabrication services including 3D bioprinting with integrated quality controls, bio-ink and biomaterial development, patient-specific tissue model creation, organ-on-chip development, tissue engineering optimization, and histological analysis.
• Start-up Incubation Program Two-year incubation program for life-sciences startups offered in partnership with UtrechtInc and supported by Province of Utrecht, providing entrepreneurial skill development, market validation, access to talent and investors, and turn-key lab space.
• Organ-on-chip MasterClass Three-day hands-on training program for scientists from academia and industry on organ-on-chip systems, delivered with AZAR Innovations, Ombion Center for Animal-free Biomedical Translation, and hDMT. Academic pricing from €1,395 and industrial pricing from €2,175.

Quantifiable outcome

• Seamless transition from research to clinical production through integrated facilities
• +1 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

16 partnerships are on record, tiered core, major and secondary.

• RegMed XBcoreStrategic or Co-development Partner · 8 April 2021RegMed XB (Regenerative Medicine Crossing Borders) is a public-private partnership bringing together research institutions, governments, provinces, health funds, and industrial partners to develop therapies for chronic diseases. ICAT is part of the RegMed XB Pilot Factory infrastructure spanning 4 Dutch clusters (Leiden, Utrecht, Eindhoven, Maastricht) plus Leuven.
• UtrechtInccoreStrategic or Co-development PartnerPartnership offering a 2-year startup incubation program for life-sciences startups with support from Province of Utrecht. ICAT provides access to facilities and expert team while UtrechtInc offers entrepreneurial skill development and business mentorship.
• Plus Ultra Utrecht / Kadans Science PartnercoreStrategic or Co-development PartnerICAT joined Plus Ultra Utrecht at Utrecht Science Park Zeist in 2026, operating the Shared Open Innovation Lab in this state-of-the-art facility. Kadans Science Partner manages the building offering 23,000 m² of laboratory, office, and startup space.
• UMC UtrechtcoreStrategic or Co-development PartnerPrimary institutional partner and host. ICAT is established within the UMC Utrecht ecosystem, with QP batch release services provided by the Pharmacy of UMC Utrecht.
• Utrecht UniversitymajorStrategic or Co-development PartnerPartner institution within Utrecht research cluster contributing faculty from Science and Veterinary Medicine departments.
• Prinses Máxima Center for Pediatric OncologymajorStrategic or Co-development PartnerResearch partner facilitating clinical testing and implementation of advanced therapies within Utrecht Science Park ecosystem.
• Hubrecht InstitutemajorStrategic or Co-development PartnerResearch partner contributing to the Utrecht research cluster for reproducible development of regenerative therapies.
• NXTGEN HightechmajorStrategic or Co-development PartnerNational Growth Fund consortium partner focused on building and scaling technology and infrastructure for ATMP production in Netherlands.
• Biotech BoostermajorStrategic or Co-development PartnerNational Growth Fund program supporting commercialization of biotechnology findings in the Netherlands, collaborating to bring innovative medicines to market.
• Oncode AcceleratormajorStrategic or Co-development PartnerNational Growth Fund consortium building infrastructure for production of advanced therapy medicinal products in the Netherlands.
• AZAR InnovationssecondaryStrategic or Co-development PartnerPartner in Organ-on-chip MasterClass 2026, contributing expertise in animal-free biomedical translation.
• Ombion Center for Animal-free Biomedical TranslationsecondaryStrategic or Co-development PartnerPartner in Organ-on-chip MasterClass 2026, providing expertise in alternative testing methods.
• hDMT (Human Organ and Disease Model Technologies)secondaryStrategic or Co-development PartnerPartner in Organ-on-chip MasterClass 2026, providing institute expertise in organ-on-chip developments.
• Smart BioMaterials Center (SBMC)majorStrategic or Co-development PartnerConsortium partner in RegMed XB Pilot Factory focusing on biomaterials pilot line in Eindhoven.
• NecstGen (Dutch Center for Clinical Advancement of Stem cell and Gene Therapies)majorStrategic or Co-development PartnerRegMed XB partner in Leiden operating stem cell pilot line within the Pilot Factory infrastructure.
• ReGEN BiomedicalmajorStrategic or Co-development PartnerRegMed XB partner in Maastricht focused on macro-tissue production line in collaboration with Maastricht University.

Scale indicators5 records

Recent moves2 records

Expansion highlights5 records

Broad incumbents

• Catalent: Major global CDMO (now owned by Novo Holdings) with established cell therapy and viral vector capabilities. Comparable as an ATMP CDMO serving commercial biopharma clients, though its portfolio is much broader than ICAT's regenerative-medicine focus.
• Charles River Laboratories: Major preclinical and CDMO services provider with cell and gene therapy manufacturing capabilities. Comparable as an integrated CDMO serving ATMP developers, though operating across a much wider portfolio of services.
• Lonza: World's largest CDMO with significant cell and gene therapy manufacturing capacity including viral vectors and cell therapy suites. Comparable as an ATMP manufacturing services provider but operating at much greater scale and commercial reach than ICAT.
• Miltenyi Biotec: Specialized life sciences company providing cell and gene therapy manufacturing platforms (e.g., Prodigy), reagents, and contract manufacturing services. Comparable as an ATMP manufacturing technology and services provider serving academic and commercial therapy developers.
• AGC Biologics: Global CDMO with mammalian cell culture, viral vector, and gene therapy manufacturing services. Comparable as an ATMP-focused manufacturing services provider serving both early-stage developers and commercial biopharma.

Direct peers

• CCRM (Centre for Commercialization of Regenerative Medicine): Canadian non-profit regenerative medicine and cell/gene therapy development and manufacturing consortium. Comparable as an integrated academic-industry innovation center offering process development, GMP manufacturing, and incubation services for advanced therapies.
• ReGEN Biomedical: RegMed XB partner operating the macro-tissue production line in Maastricht with Maastricht University. Closely comparable as a fellow RegMed XB pilot line operator focused on regenerative medicine scale-up and GMP translation.
• Cell and Gene Therapy Catapult: UK government-backed innovation center for ATMP development with GMP manufacturing capabilities. Directly comparable as a publicly funded, non-profit ATMP translation center bridging academic research and clinical-stage manufacturing.
• NecstGen: Dutch non-profit CDMO and RegMed XB Pilot Factory partner operating the stem cell pilot line in Leiden. Directly comparable as a non-clinical-stage cell and gene therapy manufacturing and process development center within the same Dutch regenerative medicine consortium.

Others

• Plus Ultra / Kadans Science Partner: Operator of the Plus Ultra Utrecht science park facility to which ICAT is relocating. Listed as a peer because of its structural role as landlord and ecosystem orchestrator — while not a CDMO, its ecosystem strategy and tenant base directly shape ICAT's market access and growth ceiling.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/innovation-center-advanced-therapies

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Innovation Center for Advanced Therapies (ICAT)